Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment
| dc.Faculty | Endemic Diseases | en_US |
| dc.contributor.author | Musa, Ahmed M. | |
| dc.contributor.author | Khalil, Eltahir Awad G. | |
| dc.contributor.author | Mahgoub, Fawzi Abd Elrahim | |
| dc.contributor.author | Hassab, Sara Hamad | |
| dc.contributor.author | Elkadarud, Abd Elgadir Mohamed Yousif | |
| dc.contributor.editor | . | en_US |
| dc.date | 2007 | |
| dc.date.accessioned | 2015-11-12T11:25:23Z | |
| dc.date.available | 2015-11-12T11:25:23Z | |
| dc.date.issued | 2015-11-12 | |
| dc.date.submitted | 2015 | |
| dc.description.abstract | Post-kala-azar dermal leishmaniasis (PKDL) is a recognized dermatosis that follows successful treatment of visceral leishmaniasis in the Sudan. This randomized and doubleblind study aimed to assess safety, immunogenicity and curative potentials of a novel immunochemotherapy regimen in patients with persistent PKDL. Following informed consent, 30 patients were randomized to receive alum-precipitated autoclaved Leishmania major (Alum/ALM) vaccine + Bacille Calmette-Gu´erin (BCG) and sodium stibogluconate (SSG) or vaccine diluent and SSG. The SSG+Alum/ALM+BCG proved safe with minimal local adverse events. In the SSG+vaccine group, 87% of the patients were cured by day 60 compared with 53% in the SSG alone group (SSG+vaccine efficacy = 71%, 95% CI for risk ratio 0.7—1.16). On day 90 of follow-up there were two relapses in the SSG alone arm and none in the SSG+vaccine arm. Pretreatment cytokines showed high IFN- or high IFN- /IL-10 levels and leishmanin skin test (LST) non-reactivity, while healing/clinical improvement were associated with LST reactivity and low | en_US |
| dc.identifier.uri | http://khartoumspace.uofk.edu/123456789/17040 | |
| dc.publisher | university of khartoum | en_US |
| dc.subject | Visceral leishmaniasis; Post-kala-azar dermal leishmaniasis; Immunotherapy; Sodium stibogluconate; Vaccines; Sudan | en_US |
| dc.subject | Post-kala-azar dermal leishmaniasis | en_US |
| dc.subject | Immunotherapy | en_US |
| dc.title | Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment | en_US |
| dc.type | Publication | en_US |